New Treatment Destroys Kidney Tumors
Posted on: Wednesday, 29 June 2005, 18:00 CDT
WEDNESDAY, June 29 (HealthDay News) -- A minimally invasive technique that uses a heated needle to destroy malignancy is proving an effective, long-lasting treatment against kidney cancer in certain patients, researchers report.
Radiofrequency ablation uses heat created by electrical energy to destroy tumor tissue. The treatment is delivered through a thin needle that's guided to the target using CT scan, ultrasound or other imaging techniques.
Researchers at the Massachusetts General Hospital in Boston reviewed data on 16 patients with a total of 20 tumors who were treated with the new technique.
They report that within four years of treatment, five of the patients died from causes unrelated to kidney cancer. None of the remaining 11 patients experienced tumor recurrence or metastasis of the kidney tumor during the four to six years following their radiofrequency ablation therapy. The findings are published in the July issue of the Journal of Urology.
"This study shows, for the first time, that this is a very effective long-term treatment," study author Dr. W. Scott McDougal, chief of urology, said in a prepared statement.
"Right now, older patients with small lesions in limited areas of their kidneys are good candidates for this procedure. We need to wait for 10-year follow-up information to determine whether it will be appropriate for patients with a longer life expectancy," McDougal said.
More information
The American Medical Association has more about kidney cancer.
SOURCE: Massachusetts General Hospital, news release, June 20, 2005~-GEN~~KIDN~
Source: HealthSCOUT
Related Articles
- Intense Treatment Doesn’t Boost Chances for Patients With Early Bladder Cancer
- MethylGene Initiates Phase I Clinical Trial for Its Multi-Targeted (C-Met) Kinase Inhibitor, MGCD265, in Solid Tumor Cancers
- Immunicon Corporation Announces FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients With Metastatic Prostate Cancer
- CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients With Metastatic Colorectal Cancer
- CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients With Metastatic Breast Cancer
- Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Various Hematologic and Solid Tumor Cancers Presented at the American Society of Clinical Oncology 42nd Annual Meeting
- Phase II Clinical Trial of NeoPharm's LE-SN38 Initiated By NCI CALGB in Patients With Metastatic Colorectal Cancer; First Patients Treated
- Geron Announces Initiation of Clinical Trial for Its Telomerase Inhibitor Drug GRN163L in Patients With Solid Tumor Malignancies
- OvaRex MAb for Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery and Chemotherapy
- Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
 |
 |
User Comments (0)
RSS Feeds